Charles A. Rowland Jr. - 16 May 2023 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role
Director
Signature
/s/ Michael Morneau as Attorney-in-Fact
Issuer symbol
VKTX
Transactions as of
16 May 2023
Net transactions value
-$956,800
Form type
4
Filing time
18 May 2023, 18:31:30 UTC
Previous filing
04 Jan 2023
Next filing
12 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VKTX Common Stock, par value $0.00001 per share Options Exercise $43,200 +40,000 +133% $1.08* 70,000 16 May 2023 Direct F1
transaction VKTX Common Stock, par value $0.00001 per share Sale $1,000,000 -40,000 -57% $25.00 30,000 16 May 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VKTX Stock Option (Right to Buy) Options Exercise $0 -40,000 -100% $0.000000* 0 16 May 2023 Common Stock 40,000 $1.08 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.